US functional dyspepsia drug market to grow at 5.1% CAGR till
2034. Rising GI disorders, aging population drive demand. Korea is
set to be the top performing market, exhibiting a CAGR of 7.0%
through 2034.
NEWARK,
Del., May 1, 2024 /PRNewswire/ -- The
global functional dyspepsia drug market will reach a valuation of
US$ 10.3 billion in 2024, attributed
to factors such as increasing geriatric population. The trend is
set to create new opportunities for the market, leading to a
projected CAGR of 4.8% between 2024 and 2034, and reaching a total
valuation of approximately US$ 16.4
billion by 2034.
Collaboration between pharmaceutical companies, academic
institutions, and research organizations fosters innovation in
functional dyspepsia drug development. Joint research efforts
accelerate the discovery of novel therapeutic targets and the
translation of scientific findings into clinical applications.
Request A Report
Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-19518
Growing acceptance and utilization of complementary and
alternative medicine approaches, such as herbal remedies,
acupuncture, and mind body therapies, create opportunities for the
development of natural or herbal based pharmacological
treatments.
Investments in healthcare infrastructure, including the
establishment of specialized gastrointestinal clinics and endoscopy
centers, improve access to diagnostic services and specialist care
for patients with functional dyspepsia. The infrastructure
development supports the diagnosis and management of the condition,
fuelling the market growth.
Harmonization of regulatory standards and the establishment of
expedited approval pathways for gastrointestinal drugs across
different regions streamline the drug development process.
It also facilitates market entry, encouraging investment in
functional dyspepsia drug development. Research into the role of
gut microbiota in gastrointestinal health has led to interest in
developing drugs that modulate the microbiome to alleviate
functional dyspepsia symptoms.
Probiotics, prebiotics, and fecal microbiota transplantation are
areas of exploration, offering potential for novel treatment
options. Advancements in regenerative medicine, including tissue
engineering and stem cell therapies, offer potential for tissue
repair and regeneration in gastrointestinal disorders like
functional dyspepsia.
Regenerative approaches may provide long term therapeutic
benefits and address underlying pathologies. Emphasis on patient
reported outcomes and patient preferences in drug development
processes promotes the development of drugs that align with patient
needs and preferences.
Patient centric approaches enhance treatment satisfaction,
adherence, and overall healthcare outcomes. The digitization of
healthcare records and the widespread adoption of electronic health
record systems facilitate data sharing and real time monitoring of
patient outcomes.
Key Takeaways from the Market Study:
- Global functional dyspepsia drug market was valued at
US$ 9.7 billion in 2023.
- From 2019 to 2023, the market demand expanded at a CAGR of
6.5%.
- The market in Korea to expand at a CAGR of 7.0% through
2034.
- By indication, the functional dyspepsia segment to account for
a CAGR of 4.6% through 2034.
- The market in China will
expand at a CAGR of 5.5% through 2034.
- In terms of channel, the over the counter segment to account
for a CAGR of 4.4% through 2034.
"EHR integration with decision support tools enhances
clinical decision making and improves the management of functional
dyspepsia," opines Sabyasachi
Ghosh Associate Vice President at Future Market Insights
(FMI).
Request Customization of Report:
https://www.futuremarketinsights.com/customization-available/rep-gb-19518
Competitive Landscape:
The functional dyspepsia drug market is characterized by a
diverse array of pharmaceutical companies, research institutions,
and healthcare organizations striving to develop and commercialize
innovative treatments for functional dyspepsia.
Company Portfolio:
- Salix Pharmaceuticals, Inc. specializes in developing and
commercializing gastrointestinal therapeutics for conditions such
as functional dyspepsia. The company offers a range of products
targeting different aspects of gastrointestinal health, including
medications for symptom relief and disease management.
- Abbott Laboratories is a diversified healthcare company with a
presence in various therapeutic areas, including gastroenterology.
Abbott offers medications such as proton pump inhibitors, antacids,
and digestive enzyme supplements.
Report Scope:
Attribute
|
Details
|
Estimated Market
Size in 2024
|
US$ 10.3
billion
|
Projected Market
Valuation in 2034
|
US$ 16.4
billion
|
Value-based CAGR
2024 to 2034
|
4.8 %
|
Forecast
Period
|
2024 to 2034
|
Historical Data
Available for
|
2019 to 2023
|
Market
Analysis
|
Value in US$
billion
|
Key Regions
Covered
|
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- The Middle East & Africa
|
Key Market Segments
Covered
|
- Indication
- Drug Type
- Medication
- Channel
- Distribution Channel
- Region
|
Key Countries
Profiled
|
- The United States
- Canada
- Brazil
- Mexico
- Germany
- France
- France
- Spain
- Italy
- Russia
- Poland
- Czech Republic
- Romania
- India
- Bangladesh
- Australia
- New Zealand
- China
- Japan
- South Korea
- GCC countries
- South Africa
- Israel
|
Key Companies
Profiled
|
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
- Salix Pharmaceuticals Inc.
- Abbott Laboratories
- Pfizer Inc.
- Sanofi SA
- Procter & Gamble
- Haleon plc
- ANI Pharmaceuticals, Inc.
- Dr. Reddy's Laboratories Ltd.
|
Get a Purchase on the Report:
https://www.futuremarketinsights.com/checkout/19518
Segmentation Analysis of the Functional Dyspepsia Drug
Market:
By Indication:
- Functional Dyspepsia
- Organic Dyspepsia
By Drug Type:
- Proton Pump Inhibitors
- H-2-Receptor Antagonists
- Antacids
- Antibiotics
- Prokinetics
- Antidepressants
By Medication:
- Branded Medicine
- Generic Medicine
By Channel:
- Over the Counter
- Prescription
By Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- The Middle East and
Africa
Author By:
Sabyasachi Ghosh (Associate Vice
President at Future Market Insights, Inc.) holds over 12 years of
experience in the Healthcare, Medical Devices, and Pharmaceutical
industries. His curious and analytical nature helped him shape his
career as a researcher.
Identifying key challenges faced by clients and devising robust,
hypothesis-based solutions to empower them with strategic
decision-making capabilities come naturally to him. His primary
expertise lies in areas such as Market Entry and Expansion
Strategy, Feasibility Studies, Competitive Intelligence, and
Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored
numerous publications and has been cited in journals, including The
Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI's related ongoing Coverage
on Healthcare Market Insights Domain:
General Anesthesia Drugs Market Size: The global general
anesthesia drugs market size is estimated at US$ 4,978.1 million in 2023. Projections indicate
a steady growth with a steady CAGR of 3.3% anticipated between 2023
and 2033. This trajectory is expected to lead the market to exceed
US$ 6,898.4 million by 2033.
Psychotropic Drugs Market Share: The global Psychotropic
Drugs Market size is US$ 21,269.4
million in 2023 and is expected to reach US$ 28,876.2 million by 2033. The global market
is estimated to expand at a CAGR of 3.1% during the forecast
period.
Lip Filler Market Growth: The lip filler market size
is eyeing a valuation of US$ 738.2
million by 2034. The expansion is estimated at a 3.6% CAGR
until 2034. In 2024, the valuation stands at US$ 518.3 million.
Nuclear Imaging Equipment Market Trends: The sales of nuclear
imaging equipment are estimated to evolve at a CAGR of 5.4% between
2024 and 2034. The nuclear imaging equipment market size
is expected to expand from US$ 3
billion in 2024 to US$ 5.1
billion through 2034.
Aesthetic Medical Device Market Outlook: The aesthetic
medical device market is valued at US$
13.73 billion in 2024 and is projected to reach US$ 18.82 billion by 2034, exhibiting a CAGR of
3.20% over the forecast period.
Infusion Pump Market Overview: The infusion pump
market is expected to expand at a CAGR of 7.2% over the
projected period. The market value is projected to increase from
US$ 104.7 million in 2024 to
US$ 209.8 million by 2034.
CTNG Testing Market Development: The CTNG testing
market is projected to be worth US$ 1.8
billion in 2024. The market is anticipated to reach
US$ 3.9 billion by 2034. The market
is further expected to surge at a CAGR of 8.0% during the forecast
period 2024 to 2034.
GLP-1 Receptor Agonist Market Strategy: The GLP-1 receptor
agonist market is projected to be valued at US$ 23,854.53 million in 2024 and is expected to
rise to US$ 72,127.79 million by
2034. It is expected to grow at a CAGR of 11.7% during the market
forecast period.
Disposable Spinal Instrument Market Demand: The disposable
spinal instrument market is expected to develop at a CAGR of
7.2% during the projected period. The market value is projected to
increase from US$ 70.4 million in
2024 to US$ 141.1 million by
2034.
Ultrasound Conductivity Gel Market Forecast: The ultrasound
conductivity gel market is estimated to be worth US$ 321.7 million in 2024. The market is expected
to grow at a CAGR of 6.7% from 2024 to 2034. By the end of the
forecast period, the market value is predicted to hit US$ 615.3 million.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the
Stevie Award, and a member of the Greater
New York Chamber of Commerce) offers profound insights into
the driving factors that are boosting demand in the market. FMI
stands as the leading global provider of market intelligence,
advisory services, consulting, and events for the Packaging, Food
and Beverage, Consumer Technology, Healthcare, Industrial, and
Chemicals markets. With a vast team of over 400 analysts worldwide,
FMI provides global, regional, and local expertise on diverse
domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware -
19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn | Twitter | Blogs | YouTube
Logo:
https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/global-functional-dyspepsia-drug-market-to-reach-a-valuation-of-us-16-4-billion-by-2034--future-market-insights-inc-projection-302132010.html
SOURCE Future Market Insights